XML 47 R24.htm IDEA: XBRL DOCUMENT v3.22.2.2
Intangible Assets and Goodwill (Tables)
 9 Months Ended
Oct. 02, 2022
Goodwill and Intangible Assets Disclosure [Abstract]  
Intangible Assets and Goodwill
(Dollars in Millions)October 2, 2022January 2, 2022
Intangible assets with definite lives:  
Patents and trademarks — gross(1)
$35,132 38,572 
Less accumulated amortization(20,116)(20,088)
Patents and trademarks — net15,016 18,484 
Customer relationships and other intangibles — gross22,302 23,011 
Less accumulated amortization(12,406)(11,925)
Customer relationships and other intangibles — net(2)
9,896 11,086 
Intangible assets with indefinite lives:  
Trademarks6,648 6,985 
Purchased in-process research and development(3)
8,776 9,837 
Total intangible assets with indefinite lives15,424 16,822 
Total intangible assets — net$40,336 46,392 
(1)The change in intangible assets with definite lives is primarily the result of currency translation effects.
(2)The majority is comprised of customer relationships
(3)In the fiscal first quarter of 2022, the Company recorded an intangible asset impairment charge of approximately $0.6 billion related to an in-process research and development asset, bermekimab (JnJ-77474462), an investigational drug for the treatment of Atopic Dermatitis (AD) and Hidradenitis Suppurativa (HS). Additional information regarding efficacy of the AD indication became available which led the Company to the decision to terminate the development of bermekimab for AD. The remaining reduction was driven by assets that reached commercialization and are now classified as having definite lives.
In October 2022, subsequent to the fiscal third quarter, additional information regarding efficacy of the HS indication became available which led the Company to the decision to terminate the development of bermekimab for HS. The Company will record a charge of approximately $0.2 billion in the fiscal fourth quarter related to this impairment. The Company acquired all rights to bermekimab from XBiotech, Inc. in the fiscal year 2020.
Goodwill
Goodwill as of October 2, 2022 was allocated by segment of business as follows:
(Dollars in Millions)Consumer HealthPharmaceuticalMedTechTotal
Goodwill at January 2, 2022$9,810 10,580 14,856 35,246 
Goodwill, related to acquisitions— — 195 195 
Currency translation/Other(1,037)(920)(101)(2,058)
Goodwill at October 2, 2022$8,773 9,660 14,950 33,383 
Intangible Asset Amortization Expense
The estimated amortization expense for approved products, before tax, for the five succeeding years is approximately:
(Dollars in Millions)
20222023202420252026
$4,3004,3004,1003,4002,800